Innovative MedTech, Inc. has completed its planned corporate rebranding and name change to AnTix Holdings, Inc., to better align with the new strategic direction of the company. This transformation marks a significant pivot from the company's previous medical technology focus to the growing online ticketing and entertainment technology sector. Through this rebranding, the company is expanding into a market where it sees meaningful opportunities to apply artificial intelligence and Web 3.0 tools to improve the ticketing and live experience for consumers and partners alike.
Michael J. Friedman, President and CEO of AnTix Holdings, Inc., stated that the company's ticketing technology has already begun generating revenues and believes this will provide a strong foundation for the next phase of growth. The company's goal is to build value through innovation, execution and acquisition in a market that Friedman describes as ripe for significant technological change. The rebranding represents an exciting milestone for the company as it transitions into this new business direction while maintaining its focus on strengthening the company's position and appeal to investors.
The formal name change process began on September 19, 2025, when the company filed with the State of Delaware a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to change the corporate name from Innovative MedTech, Inc. to AnTix Holdings, Inc. While the common stock will continue to trade under the ticker symbol IMTH temporarily, the company intends to file with FINRA to effectuate both the name change and a new ticker symbol. Outstanding stock certificates for shares of the company remain valid and do not need to be exchanged at this time due to the name change.
AnTix Holdings, Inc. now positions itself as a technology company that delivers artificial intelligence to online ticketing, with a mission to bring transparency, efficiency and personalization to the ticketing and entertainment industry. The company maintains its connection to its medical technology roots through its exclusive licensing arrangement for the Oral Thrush application of Shear Kershman Labs' BioViscid™ bio-adhesive encapsulation. Additional information about the company's new direction and services can be found at https://www.antixholdings.com.
